Cases

Search for a case

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Cases

January 18, 2023

Leap Therapeutics, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Leap Therapeutics, Inc. (“Leap” or the “Company”) (NASDAQ: LPTX), in connection with the proposed purchase of Flame Biosciences, Inc. (“Flame”). Under the terms of the merger agreement, the Company will issue approximately 19,794,373 shares of its common stock and approximately 136,833 shares of a newly designated Series X non-voting convertible preferred stock to Flame shareholders.

Join Case →

January 17, 2023

Calyxt, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Calyxt, Inc. (“Calyxt” or the “Company”) (NASDAQ:CLXT), in connection with the proposed acquisition of the Company by Cibus (“Cibus”). Under the terms of the merger agreement, the Company will issue shares of its common stock to Cibus shareholders in an exchange ratio such that upon completion of the merger, Calyxt shareholders will only own approximately 5% of the newly combined company while Cibus shareholders will own 95%.

Join Case →

January 10, 2023

DCP Midstream, LP Investigation

We are investigating possible violations of law connected with the proposed acquisition of DCP Midstream, LP (“DCP Midstream”) (NYSE: DCP) by Phillips 66 (NYSE: PSX). Under the terms of the merger agreement, the Company’s shareholders will receive $41.75 in cash for each DCP Midstream common unit owned.

Join Case →

January 9, 2023

Duck Creek Technologies, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Duck Creek Technologies, Inc. (“Duck Creek” or the Company”) (NASDAQ: DCT), in connection with the proposed acquisition of the Company by Vista Equity Partners (“Vista”). Under the terms of the merger agreement, the Company’s shareholders will receive $19.00 in cash for each share of Duck Creek common stock owned.

Join Case →

January 9, 2023

Paya Holdings Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Paya Holdings Inc. (“Paya” or the “Company”) (NASDAQ: PAYA) in connection with the proposed acquisition of the Company by Nuvei Corporation (NASDAQ: NVEI) via tender offer. Under the terms of the merger agreement, the Company’s shareholders will receive $9.75 in cash for each share of Paya common stock owned.

Join Case →

January 9, 2023

CinCor Pharma, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of CinCor Pharma, Inc. (“CinCor” or the “Company”) (NASDAQ: CINC), in connection with the proposed acquisition of the Company by Astra Zeneca PLC (NASDAQ: AZN) via tender offer. Under the terms of the merger agreement, the Company’s shareholders will receive $26.00 in cash for each share of CinCor common stock owned, plus a non-tradable contingent value right (“CVR”) of $10.00.

Join Case →

January 9, 2023

Albireo Pharma, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Albireo Pharma, Inc. (“Albireo” or the “Company”) (NASDAQ: ALBO), in connection with the proposed acquisition of the Company by Ipsen S.A. (OTC: IPSEY) via tender offer. Under the terms of the merger agreement, the Company’s shareholders will receive $42.00 in cash for each share of Albireo common stock owned, plus one contingent value right (“CVR”) per share. Each CVR will entitle its holder to deferred cash payments of $10.00 per CVR.

Join Case →

January 4, 2023

Catalyst Biosciences, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Catalyst Biosciences, Inc. (“Catalyst” or the “Company”) (NASDAQ: CBIO), in connection with the proposed purchase of GNI Group Ltd.’s (“GNI”) proprietary new chemical entity F351 (“F351”). This purchase will transfer the global rights to F351 (excluding Mainland China) to Catalyst in consideration of 6,266,521 shares of common stock and 12,340 shares of a new series of preferred stock (“Series X”) with economic rights equivalent to the Company’s common stock to be paid for GNI’s 65.18% interest of Beijing Continent (“Continent”), a China based commercial-stage pharmaceutical company marketing pirfenidone and having the rights to F351 in China.

Join Case →

January 4, 2023

Horizon Global Corporation Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Horizon Global Corporation (“Horizon” or the “Company”) (NYSE: HZN) in connection with the proposed acquisition of the Company by First Brands Group, LLC, via tender offer. Under the tender offer, the Company’s shareholders will receive $1.75 in cash for each share of Horizon common stock owned.

Join Case →

We will fight for you and have your back no matter what. Join the tens of thousands of people we’ve helped.

Cases

Search for a case

Cases

Leap Therapeutics, Inc. Investigation

Calyxt, Inc. Investigation

DCP Midstream, LP Investigation

Duck Creek Technologies, Inc. Investigation

Paya Holdings Inc. Investigation

CinCor Pharma, Inc. Investigation

Albireo Pharma, Inc. Investigation

Catalyst Biosciences, Inc. Investigation

Horizon Global Corporation Investigation

Where to find us?

new york

california

georgia

NEW JERSEY